Zareifar S, Shorafa S, Haghpanah S, Karamizadeh Z, Adelian R
Hematology Research Center,Pediatric Hematology/Oncology department, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Pediatrics, Shiraz University of Medical Sciences, Shiraz, Iran.
Iran J Ped Hematol Oncol. 2015;5(3):116-24. Epub 2015 Jul 20.
Obesity is a medical problem in survivors of childhood acute lymphoblastic leukemia. Obesity is associated with many complications, so it is important to investigate the respective etiology. Leptin is a protein synthesized in the fatty tissue and is effective in the control of obesity. Survey of leptin in acute lymphoblastic leukemia (ALL) survivors could be helpful in controlling obesity.
In this prospective study, 53 pediatric patients diagnosed with ALL between 2006 and 2012 from Southern Iran, were enrolled. We examined body mass index (BMI) status and performed laboratory measuring tests including triglyceride, cholesterol, fasting blood sugar, leptin at diagnosis time and then every 6 months and in the last visit.
Participants consisted of 35 male and 18 female patients. At the time of diagnosis, 5.66% were overweight or obese, whereas at the end of treatment, approximately 13 patients (24.53%) were overweight or obese. The median and interquartile range (IQR) for blood leptin level were significantly higher for obese patients than other patients (885, 1120 vs. 246, 494 pg/ml), (P=0.030). The median and IQR were also significantly higher in females than in males (861, 969 vs. 204, 267 pg/ml), (P=0.006).
Obesity is a complication of ALL treatment. It is associated with elevated blood leptin level. Hypothalamus leptin resistance in obese patients should be considered. In each visit, clinicians should weight and their patient's BMI take into account.
肥胖是儿童急性淋巴细胞白血病幸存者面临的一个医学问题。肥胖与许多并发症相关,因此研究其各自的病因很重要。瘦素是一种在脂肪组织中合成的蛋白质,对控制肥胖有效。调查急性淋巴细胞白血病(ALL)幸存者的瘦素水平可能有助于控制肥胖。
在这项前瞻性研究中,纳入了2006年至2012年间来自伊朗南部的53名诊断为ALL的儿科患者。我们检查了体重指数(BMI)状况,并进行了实验室测量测试,包括甘油三酯、胆固醇、空腹血糖、诊断时以及之后每6个月和最后一次就诊时的瘦素水平。
参与者包括35名男性和18名女性患者。诊断时,5.66%的患者超重或肥胖,而在治疗结束时,约13名患者(24.53%)超重或肥胖。肥胖患者的血液瘦素水平中位数和四分位间距(IQR)显著高于其他患者(885,1120对246,494 pg/ml),(P = 0.030)。女性的中位数和IQR也显著高于男性(861,969对204,267 pg/ml),(P = 0.006)。
肥胖是ALL治疗的一种并发症。它与血液瘦素水平升高有关。应考虑肥胖患者的下丘脑瘦素抵抗。每次就诊时,临床医生都应考虑患者的体重和BMI。